Referencia número: HY-18085

Quercetin

224 Cited Publications

Revisión del cliente

Based on 224 publication(s) in Google Scholar

Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.80%
No. CAS: 117-39-5
Fòrmula: C₁₅H₁₀O₇
Peso molecular:302.24

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Quercetin Chemical Structure

No. CAS: 117-39-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (224)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively^[1].

IC₅₀ & Target^[1]

PI3Kδ

2.4 μM (IC₅₀)

PI3Kγ

3 μM (IC₅₀)

PI3Kβ

5.4 μM (IC₅₀)

Autophagy

Mitophagy

Ver todos los productos específicos de isoformas PI3K :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	21.18 μM Compound: 1, Que	Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A2780	GI₅₀	19.7 μM Compound: Quercetin	Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay Growth inhibition of human A2780 cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
A-375	IC₅₀	25.13 μM Compound: 1, Que	Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-375	IC₅₀	1.54 ng/mL Compound: 2	Cytotoxicity in human A375 cells Cytotoxicity in human A375 cells	[PMID: 28793973]
A-431	IC₅₀	1.8 μg/mL Compound: quercetin	Inhibition of phosphatidylinositol 4-kinase in human A431 cell membrane by liquid scintillation counting Inhibition of phosphatidylinositol 4-kinase in human A431 cell membrane by liquid scintillation counting	[PMID: 1666120]
A-431	IC₅₀	23.04 μM Compound: 1, Que	Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-431	IC₅₀	34.37 μM Compound: 1, Que	Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A549	IC₅₀	>20 mg/mL Compound: 18	Cytotoxicity against human A549 cells after 3 days by SRB assay Cytotoxicity against human A549 cells after 3 days by SRB assay	[PMID: 15568778]
A549	IC₅₀	6.2 μM Compound: 1	Anticancer activity against human A549 cells by HTS assay Anticancer activity against human A549 cells by HTS assay	[PMID: 25139569]
A549	IC₅₀	>10 μg/mL Compound: Compound 4	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 25862199]
A549	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 28165740]
A549	IC₅₀	13 μM Compound: Quer	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
ANN-1	IC₅₀	32.5 μM Compound: (2) quercetin	Cytotoxic effect on v-abl transformed murine ANN-1 cells Cytotoxic effect on v-abl transformed murine ANN-1 cells	[PMID: 8201603]
B16-4A5	IC₅₀	15 μM Compound: 17	Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs	[PMID: 20189399]
B16-4A5	IC₅₀	15 μM Compound: 7	Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis	[PMID: 25987378]
BALB/3T3	IC₅₀	217 μM Compound: 5	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BT-549	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 28165740]
BV-2	IC₅₀	29.6 μM Compound: 5, quercetin	Inhibition of LPS-induced NO production in mouse BV2 cells Inhibition of LPS-induced NO production in mouse BV2 cells	[PMID: 18178435]
BV-2	IC₅₀	10 μM Compound: Quercetin	Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production by Griess assay Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production by Griess assay	[PMID: 24707938]
BV-2	IC₅₀	4.3 μM Compound: Quercetin	Inhibition of LPS-stimulated NO production in human BV2 cells after 24 hrs by Griess assay Inhibition of LPS-stimulated NO production in human BV2 cells after 24 hrs by Griess assay	[PMID: 25127164]
BV-2	IC₅₀	17.4 μM Compound: quercetin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess assay	[PMID: 26327273]
BV-2	EC₅₀	11 μM Compound: quercetin	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay	[PMID: 26473791]
BV-2	IC₅₀	8.7 μM Compound: Quercetin	Inhibition of LPS-induced nitric oxide production in human BV2 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in human BV2 cells after 24 hrs by Griess assay	[PMID: 26696523]
BV-2	IC₅₀	15.13 μM Compound: Quercetin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay	[PMID: 27335254]
BV-2	IC₅₀	39.46 μM Compound: 1	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction	[PMID: 27623545]
BV-2	IC₅₀	19.11 μM Compound: 10	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay	[PMID: 28165740]
BV-2	IC₅₀	16.3 μM Compound: Quercetin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production by Griess reagent based spectrophotometric analysis Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production by Griess reagent based spectrophotometric analysis	[PMID: 29122483]
BV-2	IC₅₀	7.2 μM Compound: Quercetin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 29303577]
BV-2	IC₅₀	4.3 μM Compound: Quercetin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 30119995]
BV-2	IC₅₀	2.4 μM Compound: Quercetin	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells after 24 hrs by Griess assay	[PMID: 30132670]
BV-2	IC₅₀	2.4 μM Compound: Quercetin	Antineuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess reagent based assay Antineuroinflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess reagent based assay	[PMID: 31244147]
BV-2	EC₅₀	10.5 μM Compound: Quercetin	Inhibition of LPS-induced NO production in mouse BV-2 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse BV-2 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 34315042]
BV-2	EC₅₀	9.56 μM Compound: Qc	Inhibition of LPS induced NO production in mouse BV-2 cells by Griess reagent based analysis Inhibition of LPS induced NO production in mouse BV-2 cells by Griess reagent based analysis	[PMID: 34875520]
BV-2	IC₅₀	2.45 μM Compound: Quercetin	Antineuroinflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay Antineuroinflammatory activity against mouse BV-2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess assay	[PMID: 34978437]
BV-2	IC₅₀	6.5 μM Compound: Quercetin	Inhibition of NO production in LPS-induced mouse BV-2 cells incubated for 24 hrs by Griess reagent based microplate reader analysis Inhibition of NO production in LPS-induced mouse BV-2 cells incubated for 24 hrs by Griess reagent based microplate reader analysis	[PMID: 36579935]
BV-2	IC₅₀	7.41 μM Compound: Quercetin	Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay	[PMID: 37530709]
BV-2	IC₅₀	12.58 μM Compound: 96; 99	Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse BV-2 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 37683361]
BV-2	IC₅₀	10 μM Compound: Quercetin	Antineuroinflammatory activity in LPS induced mouse BV-2 cells assessed as inhibition of NO production pretreated for 4 hrs followed by LPS addition and measured after 24 hrs by griess reagent based assay Antineuroinflammatory activity in LPS induced mouse BV-2 cells assessed as inhibition of NO production pretreated for 4 hrs followed by LPS addition and measured after 24 hrs by griess reagent based assay	[PMID: 38095929]
BV-2	IC₅₀	9.8 μM Compound: Quercetin	Antineuroinflammatory activity in LPS induced mouse BV-2 cells assessed as inhibition of NO production pretreated for 3 hrs followed by LPS addition and measured after 21 hrs by griess reagent based assay Antineuroinflammatory activity in LPS induced mouse BV-2 cells assessed as inhibition of NO production pretreated for 3 hrs followed by LPS addition and measured after 21 hrs by griess reagent based assay	[PMID: 39140432]
BXPC-3	IC₅₀	24.12 μM Compound: 1, Que	Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
BXPC-3	IC₅₀	16 μM Compound: Quer	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
C13	IC₅₀	37.62 μM Compound: 1, Que	Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
C2C12	IC₅₀	30.79 μg/mL Compound: 3	Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse C2C12 cells assessed as reduction in cell viability by MTT assay	[PMID: 33412152]
C6	IC₅₀	18.38 μM Compound: 51	Inhibition of cell proliferation of rat C6 cells assessed as cell viability after 72 hrs by sulforhodamine B assay Inhibition of cell proliferation of rat C6 cells assessed as cell viability after 72 hrs by sulforhodamine B assay	[PMID: 25442304]
C8166	CC₅₀	104.9 μg/mL Compound: 1	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	2.05 μg/mL Compound: 1	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
Calu-1	IC₅₀	23.58 μM Compound: 1	Anticancer activity against human Calu1 cells by HTS assay Anticancer activity against human Calu1 cells by HTS assay	[PMID: 25139569]
CCRF-CEM	IC₅₀	>10 μg/mL Compound: 8	Cytotoxicity against human CEM cells after 3 days by MTT assay Cytotoxicity against human CEM cells after 3 days by MTT assay	[PMID: 11421746]
CHO	EC₅₀	>100 μM Compound: quercetin	Displacement of [3H]8-OH-DPAT from human recombinant 5HT1A receptor expressed in CHO cells Displacement of [3H]8-OH-DPAT from human recombinant 5HT1A receptor expressed in CHO cells	[PMID: 16562853]
COLO 201	IC₅₀	19 μM Compound: Quer	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
CT26	IC₅₀	14.4 μM Compound: 1	Antiproliferative activity against mouse CT26 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Antiproliferative activity against mouse CT26 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36599228]
CT26	IC₅₀	14.4 μM Compound: 1	Antiproliferative activity against mouse CT26 cells harboring active Wnt/beta-catenin signal assessed as inhibition of cell proliferation by CCK8 assay Antiproliferative activity against mouse CT26 cells harboring active Wnt/beta-catenin signal assessed as inhibition of cell proliferation by CCK8 assay	[PMID: 38097141]
CWR22R	IC₅₀	15.5 μM Compound: 16	Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer	[PMID: 22789812]
DU-145	EC₅₀	>100 μM Compound: Quercetin	Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay	[PMID: 21090565]
DU-145	IC₅₀	>100 μM Compound: Quercetin	Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
DU-145	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay	[PMID: 28760528]
DU-145	IC₅₀	>100 μM Compound: Quercetin	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay	[PMID: 30165345]
EA.hy 926	EC₅₀	2669.3 nM Compound: Quercetin	Cytoprotective activity against H2O2-induced toxicity in human EA.hy 926 cells assessed as protective rate pretreated with compound for 4 hrs followed by incubation with H2O2 for 2 hrs by absorbance based analysis Cytoprotective activity against H2O2-induced toxicity in human EA.hy 926 cells assessed as protective rate pretreated with compound for 4 hrs followed by incubation with H2O2 for 2 hrs by absorbance based analysis	[PMID: 37625288]
H9	EC₅₀	132 μM Compound: 4	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	132 μM Compound: 4	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9	EC₅₀	1.6 μg/mL Compound: 2	Inhibitory activity against HIV-1 IIIB replication in H9 cell line Inhibitory activity against HIV-1 IIIB replication in H9 cell line	10.1016/0960-894X(94)80015-4
H9	IC₅₀	<4 μg/mL Compound: 2	Inhibitory activity against H9 cells uninfected with HIV-1 Inhibitory activity against H9 cells uninfected with HIV-1	10.1016/0960-894X(94)80015-4
HCT-116	EC₅₀	>100 μM Compound: Quercetin	Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 21090565]
HCT-116	IC₅₀	23 μM Compound: 2	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	5.7 μM Compound: 2	Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	6.7 μM Compound: 2	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 22212721]
HCT-116	IC₅₀	43.87 μM Compound: Quercetin	Cytotoxicity against human HCT-116 cells overexpressing MCT-1 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells overexpressing MCT-1 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33221062]
HCT-116	IC₅₀	10.44 μM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36599228]
HCT-116	IC₅₀	11.41 μM Compound: 1	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation by CCK8 assay	[PMID: 38097141]
HCT-15	IC₅₀	16.35 μM Compound: 1, Que	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HEK293	IC₅₀	1.54 μM Compound: 20	Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol	[PMID: 18533708]
HEK293	IC₅₀	0.68 μM Compound: 7a	Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay	[PMID: 20731357]
HEK293	IC₅₀	54.65 μM Compound: 1, Que	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HEK293	IC₅₀	6.5 μM Compound: 22	Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay	[PMID: 30943030]
HeLa	IC₅₀	≥10 μM Compound: quercetin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19278239]
HeLa	IC₅₀	3.56 μM Compound: 1	Anticancer activity against human HeLa cells by HTS assay Anticancer activity against human HeLa cells by HTS assay	[PMID: 25139569]
HeLa	IC₅₀	8.26 μg/mL Compound: Compound 4	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 25862199]
HeLa	GI₅₀	17.7 μM Compound: Quercetin	Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay Growth inhibition of human HeLa cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
HeLa	IC₅₀	22.5 μM Compound: Quercetin	Cytotoxicity against human HeLa cells overexpressing MCT-1 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells overexpressing MCT-1 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 33221062]
HeLa	IC₅₀	4 μM Compound: 30	Cytotoxicity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell viability incubated for 48 hrs by MTT assay	[PMID: 33355454]
HepG2	IC₅₀	>10 μM Compound: quercetin	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 19583252]
HepG2	IC₅₀	30.9 μM Compound: 32	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 21726077]
HepG2	IC₅₀	11 μM Compound: Quercetin	Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced intracellular peroxyl radical scavenging activity by measuring ROS production measured every 5 mins for 1 hr by absorbance assay Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced intracellular peroxyl radical scavenging activity by measuring ROS production measured every 5 mins for 1 hr by absorbance assay	[PMID: 24471493]
HepG2	EC₅₀	4.63 μM Compound: QE	Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay	[PMID: 26974372]
HepG2	EC₅₀	4.63 μmol Compound: QE	Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay	[PMID: 26974372]
HepG2	IC₅₀	12 μM Compound: Quercetin	Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced peroxyl radical generation incubated for 60 mins measured for 60 mins by DCFH-DA probe based fluorescence assay Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced peroxyl radical generation incubated for 60 mins measured for 60 mins by DCFH-DA probe based fluorescence assay	[PMID: 29553260]
HepG2	IC₅₀	65 μM Compound: Quercetin	Antioxidant activity in human HepG2 cells assessed as inhibition of cumene hydroperoxide-mediated lipid peroxidation incubated for 60 mins followed by cumOOH addition for 60 mins measured for 60 mins by C11-BODIPY probe based fluorescence assay Antioxidant activity in human HepG2 cells assessed as inhibition of cumene hydroperoxide-mediated lipid peroxidation incubated for 60 mins followed by cumOOH addition for 60 mins measured for 60 mins by C11-BODIPY probe based fluorescence assay	[PMID: 29553260]
HepG2	IC₅₀	12.5 μM Compound: Quercetin	Neuroprotective activity against H202 induced oxidative stress in human HepG2 cells measured after 1 hr by DCFH-DA staining based analysis Neuroprotective activity against H202 induced oxidative stress in human HepG2 cells measured after 1 hr by DCFH-DA staining based analysis	[PMID: 37567058]
HepG2	IC₅₀	15.1 μM Compound: 96; 99	Anti-inflammatory activity against TNFalpha-induced human HepG2 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay Anti-inflammatory activity against TNFalpha-induced human HepG2 cells assessed as inhibition of NF-kappaB activity pre-indubated for 1 hr followed by TNFalpha treatment measured for 5 hrs by luciferase based assay	[PMID: 37683361]
HepG2	IC₅₀	12.5 μM Compound: Quercetin	Antioxidant activity in human HepG2 cells assessed as reduction in H2O2-induced oxidation measured after 60 mins by DCFH-DA staining method Antioxidant activity in human HepG2 cells assessed as reduction in H2O2-induced oxidation measured after 60 mins by DCFH-DA staining method	[PMID: 39002183]
HepG2 2.2.15	CC₅₀	38.1 μM Compound: quercetin	Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay	[PMID: 21401115]
HFF	IC₅₀	100 μM Compound: (2) quercetin	Inhibition of PDGF-induced mitogenesis in human foreskin fibroblasts Inhibition of PDGF-induced mitogenesis in human foreskin fibroblasts	[PMID: 8201603]
HL-60	IC₅₀	>10 μg/mL Compound: 8	Cytotoxicity against human HL60 cells after 3 days by MTT assay Cytotoxicity against human HL60 cells after 3 days by MTT assay	[PMID: 11421746]
HL-60	IC₅₀	58 μM Compound: Quercetin	Cytotoxicity against human HL60 cells after 46 hrs by MTT assay Cytotoxicity against human HL60 cells after 46 hrs by MTT assay	[PMID: 23756061]
HL-60	IC₅₀	47 μM Compound: Quercetin	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 25014747]
HL-60	IC₅₀	10 ng/mL Compound: Quercetin	Growth inhibition of human HL60 cells after 72 hrs by MTT assay Growth inhibition of human HL60 cells after 72 hrs by MTT assay	[PMID: 31398616]
HN5	IC₅₀	190 μM Compound: (2) quercetin	Cytotoxic effect on EGF-receptor overexpressing HN5 squamous carcinoma cells Cytotoxic effect on EGF-receptor overexpressing HN5 squamous carcinoma cells	[PMID: 8201603]
HOP-62	IC₅₀	7.52 μM Compound: 1	Anticancer activity against human HOP62 cells by HTS assay Anticancer activity against human HOP62 cells by HTS assay	[PMID: 25139569]
HS27	EC₅₀	>100 μM Compound: Quercetin	Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay Antiproliferative activity against human HS27 cells after 24 hrs by MTT assay	[PMID: 21090565]
Hs-578T	IC₅₀	50.54 μM Compound: Quercetin	Cytotoxicity against human Hs-578T cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human Hs-578T cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38665823]
HT-22	EC₅₀	2.98 μM Compound: Quercetin	Inhibition of glutamate-induced oxytosis of mouse hippocampal HT22 cells Inhibition of glutamate-induced oxytosis of mouse hippocampal HT22 cells	[PMID: 16392814]
HT-22	EC₅₀	11.52 μM Compound: Quercetin	Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay	[PMID: 24602904]
HT-22	EC₅₀	3.13 μM Compound: Quercetin	Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxidative damage after 24 hrs by MTT assay Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxidative damage after 24 hrs by MTT assay	[PMID: 24602904]
HT-29	EC₅₀	8.02 μM Compound: Quercetin	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
HT-29	IC₅₀	15.4 μM Compound: Quercetin	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
HT-29	IC₅₀	18 μM Compound: Quer	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Huh-7	CC₅₀	>50 μM Compound: 35	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	19.8 μM Compound: 35	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Huh-7	IC₅₀	99.97 μM Compound: 12a	Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36692498]
HUVEC	EC₅₀	18 μM Compound: Quercetin	Cytoprotective activity against H2O2-induced cell injury in HUVEC cells Cytoprotective activity against H2O2-induced cell injury in HUVEC cells	[PMID: 20621727]
HUVEC	IC₅₀	>100 μM Compound: 7	Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells Inhibition of NADPH oxidase in Homo sapiens (human) HUVEC cells	10.1007/s00044-012-0353-y
J774.2	IC₅₀	125.44 μM Compound: 2	Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay	[PMID: 19489596]
J774.A1	IC₅₀	49.1 μM Compound: 1	Inhibition of LPS-induced NO production in mouse J774.A1 cells pre-incubated with compound for 1 hr followed by LPS stimulation for 24 hrs by ELISA assay Inhibition of LPS-induced NO production in mouse J774.A1 cells pre-incubated with compound for 1 hr followed by LPS stimulation for 24 hrs by ELISA assay	[PMID: 34971873]
Jurkat	IC₅₀	5 μM Compound: Quercetin	Activity against hydrogen peroxide induced DNA damage in Jurkat T cells Activity against hydrogen peroxide induced DNA damage in Jurkat T cells	[PMID: 16392814]
Jurkat	IC₅₀	2 μM Compound: Quercetin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	3.5 μM Compound: Quercetin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
K562	IC₅₀	2.5 μM Compound: Quercetin	Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 5 days by MTT assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 5 days by MTT assay	[PMID: 29553260]
KB	IC₅₀	136 μg/mL Compound: quercetin	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 12398543]
KB	ED₅₀	25 μg/mL Compound: NSC-9219	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
L6	IC₅₀	>30 μg/mL Compound: 17	Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method	10.1039/C5MD00481K
L929	IC₅₀	>100 μM Compound: Quercetin	Cytotoxicity against mouse L929 cells after 5 days by MTS assay Cytotoxicity against mouse L929 cells after 5 days by MTS assay	[PMID: 22743241]
L929	EC₅₀	20 μM Compound: quercetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining	[PMID: 9287415]
L929	EC₅₀	26 μM Compound: quercetin	Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay	[PMID: 9287415]
LN-229	IC₅₀	12 μM Compound: Quer	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LNCaP	EC₅₀	25 μM Compound: 2, quercetin	Decrease in androgen receptor protein expression in LNCaP cells by Western blotting Decrease in androgen receptor protein expression in LNCaP cells by Western blotting	[PMID: 17383188]
LNCaP	IC₅₀	45.5 μM Compound: Quercetin	Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
LNCaP	IC₅₀	45.5 μM Compound: 1	Antiproliferative activity against human LNCAP cells after 3 days by WST1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST1 assay	[PMID: 27476422]
LNCaP	IC₅₀	45.46 μM Compound: 1	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay	[PMID: 28760528]
LNCaP	IC₅₀	45.5 μM Compound: Quercetin	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay	[PMID: 30165345]
LOX IMVI	IC₅₀	4.65 μM Compound: 1	Anticancer activity against human LOXIMVI cells by HTS assay Anticancer activity against human LOXIMVI cells by HTS assay	[PMID: 25139569]
M14	IC₅₀	12.77 μM Compound: 1	Anticancer activity against human M14 cells by HTS assay Anticancer activity against human M14 cells by HTS assay	[PMID: 25139569]
MCF-10A	IC₅₀	11.97 μM Compound: Quercetin	Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay	[PMID: 30165345]
MCF-10A	IC₅₀	9.32 μM Compound: Quercetin	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38665823]
MCF7	IC₅₀	19.5 mg/mL Compound: 18	Cytotoxicity against human MCF7 cells after 3 days by SRB assay Cytotoxicity against human MCF7 cells after 3 days by SRB assay	[PMID: 15568778]
MCF7	IC₅₀	>10 μM Compound: quercetin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19583252]
MCF7	EC₅₀	>100 μM Compound: Quercetin	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 21090565]
MCF7	IC₅₀	7.6 μM Compound: 13	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MCF7	IC₅₀	20.9 μM Compound: 1, Que	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
MCF7	IC₅₀	5 μM Compound: Quercetin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	24 μM Compound: (2) quercetin	Cytotoxic effect on MCF-7 human breast carcinoma cells Cytotoxic effect on MCF-7 human breast carcinoma cells	[PMID: 8201603]
MDA-MB-231	IC₅₀	20 μM Compound: Quer	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDCK	CC₅₀	253.8 μM Compound: 4	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 19729316]
MDCK	EC₅₀	133.6 μM Compound: 4	Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H9N2 A/Chicken/Korea/MS96/96 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	EC₅₀	43.1 μM Compound: 4	Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect	[PMID: 19729316]
MDCK	IC₅₀	6.9 μM Compound: 13	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	ED₅₀	48.2 μM Compound: 1	Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR	[PMID: 22115591]
MDCK	CC₅₀	253.8 μM Compound: QR	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay	[PMID: 31744778]
MDCK	EC₅₀	84.46 nM Compound: QR	Antiviral activity against Influenza A virus (H1N1) infected in dog MDCK cells assessed as reduction in log2HA titer incubated for 3 to 4 days by CPE assay Antiviral activity against Influenza A virus (H1N1) infected in dog MDCK cells assessed as reduction in log2HA titer incubated for 3 to 4 days by CPE assay	[PMID: 31744778]
MIA PaCa-2	IC₅₀	73.5 μM Compound: 12a	Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MIA PaCa-2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 36692498]
Monocyte	IC₅₀	120 μM Compound: quercetin	Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA	[PMID: 10096854]
MSTO-211H	GI₅₀	>20 μM Compound: Quercetin	Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay Growth inhibition of human MSTO-211H cells incubated for 72 hrs by trypan blue assay	[PMID: 32435372]
MV4-11	GI₅₀	13.1 μM Compound: 6	Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
N9	IC₅₀	10.22 μM Compound: 2	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 28073678]
NALM-6	IC₅₀	77.1 μM Compound: Quercetin	Cytotoxicity against human NALM6 cells after 46 hrs by MTT assay Cytotoxicity against human NALM6 cells after 46 hrs by MTT assay	[PMID: 23756061]
NCI/ADR-RES	IC₅₀	22.15 μM Compound: 1, Que	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
NCI-H1299	IC₅₀	13.6 μM Compound: 1	Anticancer activity against human H1299 cells by HTS assay Anticancer activity against human H1299 cells by HTS assay	[PMID: 25139569]
NCI-H157	IC₅₀	6 μM Compound: 1	Anticancer activity against human NCI-H157 cells by HTS assay Anticancer activity against human NCI-H157 cells by HTS assay	[PMID: 25139569]
NCI-H1792	IC₅₀	3.85 μM Compound: 1	Anticancer activity against human NCI-H1792 cells by HTS assay Anticancer activity against human NCI-H1792 cells by HTS assay	[PMID: 25139569]
NCI-H1944	IC₅₀	10.18 μM Compound: 1	Anticancer activity against human NCI-H1944 cells by HTS assay Anticancer activity against human NCI-H1944 cells by HTS assay	[PMID: 25139569]
NCI-H460	IC₅₀	9.62 μM Compound: 1	Anticancer activity against human H460 cells by HTS assay Anticancer activity against human H460 cells by HTS assay	[PMID: 25139569]
NCI-H460	IC₅₀	12 μM Compound: Quer	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NCI-H522	IC₅₀	5.77 μM Compound: 1	Anticancer activity against human NCI-H522 cells by HTS assay Anticancer activity against human NCI-H522 cells by HTS assay	[PMID: 25139569]
Neutrophil	IC₅₀	2.4 μM Compound: Quercetin	Inhibition of immune complex-stimulated neutrophil oxidative metabolism in New Zealand white rabbit neutrophils assessed as ROS generation after 30 mins by luminol enhanced chemiluminescence assay Inhibition of immune complex-stimulated neutrophil oxidative metabolism in New Zealand white rabbit neutrophils assessed as ROS generation after 30 mins by luminol enhanced chemiluminescence assay	[PMID: 17804122]
Neutrophil	IC₅₀	4.7 μM Compound: Quercetin	Inhibition of immune complex-stimulated neutrophil oxidative metabolism in New Zealand white rabbit neutrophils assessed as ROS generation after 30 mins by lucigenin enhanced chemiluminescence assay Inhibition of immune complex-stimulated neutrophil oxidative metabolism in New Zealand white rabbit neutrophils assessed as ROS generation after 30 mins by lucigenin enhanced chemiluminescence assay	[PMID: 17804122]
Neutrophil	IC₅₀	0.7 μM Compound: 4i	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	11.3 μM Compound: 4i	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	26 μM Compound: 4i	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	8 μM Compound: 4i	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	4.86 μM Compound: Quercetin	Antioxidant activity in human neutrophils assessed as inhibition of oxidative burst-induced ROS production by chemiluminescence assay Antioxidant activity in human neutrophils assessed as inhibition of oxidative burst-induced ROS production by chemiluminescence assay	[PMID: 24588269]
Neutrophil	IC₅₀	1.8 μM Compound: 7	Inhibition of PMA-induced oxidative burst in human neutrophils by APF assay Inhibition of PMA-induced oxidative burst in human neutrophils by APF assay	[PMID: 25151578]
Neutrophil	IC₅₀	2.7 μM Compound: 7	Inhibition of PMA-induced oxidative burst in human neutrophils by amplex red assay Inhibition of PMA-induced oxidative burst in human neutrophils by amplex red assay	[PMID: 25151578]
Neutrophil	IC₅₀	2.8 μM Compound: 7	Inhibition of PMA-induced oxidative burst in human neutrophils by chemiluminescence assay Inhibition of PMA-induced oxidative burst in human neutrophils by chemiluminescence assay	[PMID: 25151578]
Neutrophil	IC₅₀	20.4 μM Compound: Quercetin	Antiinflammatory activity against LPS-stimulated human neutrophils assessed as reduction in TNFalpha production incubated for 1 hr followed by LPS stimulation measured after 18 to 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated human neutrophils assessed as reduction in TNFalpha production incubated for 1 hr followed by LPS stimulation measured after 18 to 24 hrs by ELISA	[PMID: 30109803]
Neutrophil	IC₅₀	33 μM Compound: Quercetin	Antiinflammatory activity against LPS-stimulated human neutrophils assessed as reduction in IL-8 production incubated for 1 hr followed by LPS stimulation measured after 18 to 24 hrs by ELISA Antiinflammatory activity against LPS-stimulated human neutrophils assessed as reduction in IL-8 production incubated for 1 hr followed by LPS stimulation measured after 18 to 24 hrs by ELISA	[PMID: 30109803]
Neutrophil	IC₅₀	4.4 μM Compound: Quercetin	Antiinflammatory activity against f-MLP-stimulated human neutrophils assessed as reduction in ROS production incubated for 40 mins measured at intervals of 2 mins by luminol-dependent chemiluminescence assay Antiinflammatory activity against f-MLP-stimulated human neutrophils assessed as reduction in ROS production incubated for 40 mins measured at intervals of 2 mins by luminol-dependent chemiluminescence assay	[PMID: 30109803]
NHDF	IC₅₀	>50 μM Compound: 34	Cytotoxicity against NHDF assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against NHDF assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 28671460]
NIH3T3	IC₅₀	39.5 μM Compound: (2) quercetin	Cytotoxic effect on 3T3 cells Cytotoxic effect on 3T3 cells	[PMID: 8201603]
Osteoclast	IC₅₀	5.3 μM Compound: quercetin	Induction of mouse osteoclast apoptosis Induction of mouse osteoclast apoptosis	[PMID: 17994703]
P388	ED₅₀	40 μg/mL Compound: Quercetin	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 3404159]
PANC-1	IC₅₀	62 μM Compound: Quer	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PC-12	EC₅₀	68.3 μM Compound: Quercetin	Cytoprotective activity against H2O2-induced cell death in rat PC12 cells assessed as increase in cell viability preincubated 2 hrs before H2O2 challenge measured after 4 hrs by MTT assay Cytoprotective activity against H2O2-induced cell death in rat PC12 cells assessed as increase in cell viability preincubated 2 hrs before H2O2 challenge measured after 4 hrs by MTT assay	[PMID: 19362850]
PC-12	EC₅₀	58.4 μM Compound: Quercetin	Neuroprotective activity against H2O2-induced injury in rat PC12 cells treated 2 hrs before H2O2 challenge measured after 4 hrs by MTT assay Neuroprotective activity against H2O2-induced injury in rat PC12 cells treated 2 hrs before H2O2 challenge measured after 4 hrs by MTT assay	[PMID: 19673490]
PC-3	IC₅₀	>100 μM Compound: Quercetin	Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
PC-3	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human PC3 cells after 3 days by WST1 assay Antiproliferative activity against human PC3 cells after 3 days by WST1 assay	[PMID: 27476422]
PC-3	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay	[PMID: 28760528]
PC-3	IC₅₀	>100 μM Compound: Quercetin	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay	[PMID: 30165345]
Peritoneal macrophage	IC₅₀	36 μM Compound: kp20	Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method	[PMID: 27955927]
Peritoneal macrophage	IC₅₀	>100 μM Compound: quercetin	Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay	[PMID: 22989363]
Peritoneal macrophage	IC₅₀	80.2 μM Compound: 1	Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by AlamarBlue assay Cytotoxicity against Swiss mouse peritoneal macrophages after 72 hrs by AlamarBlue assay	[PMID: 23876028]
PWR-1E	IC₅₀	15.08 μM Compound: Quercetin	Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay	[PMID: 30165345]
RAW264.7	IC₅₀	26.8 μM Compound: Quercetin	Inhibition of LPS and INF-gamma-induced NO production in mouse RAW264.7 cells Inhibition of LPS and INF-gamma-induced NO production in mouse RAW264.7 cells	[PMID: 15043424]
RAW264.7	IC₅₀	26.8 μM Compound: Quercetin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells	[PMID: 16378364]
RAW264.7	IC₅₀	25 μM Compound: quercetin	Inhibition of LPS and INF-alpha-induced nitric oxide production in mouse RAW264.7 cells after 16 hrs Inhibition of LPS and INF-alpha-induced nitric oxide production in mouse RAW264.7 cells after 16 hrs	[PMID: 18027905]
RAW264.7	IC₅₀	26.8 μM Compound: quercetin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells	[PMID: 18027905]
RAW264.7	IC₅₀	9.6 μM Compound: quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent assay	[PMID: 19555124]
RAW264.7	IC₅₀	11.4 μM Compound: 9	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 19778086]
RAW264.7	IC₅₀	54.3 μM Compound: Quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by Griess reagent method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by Griess reagent method	[PMID: 20056545]
RAW264.7	IC₅₀	32.1 μM Compound: quercetin	Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA	[PMID: 20121165]
RAW264.7	IC₅₀	34.5 μM Compound: Quercetin	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs	[PMID: 20825224]
RAW264.7	IC₅₀	63 μM Compound: 8	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 21353543]
RAW264.7	IC₅₀	66.6 μM Compound: 8	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs	[PMID: 21353543]
RAW264.7	IC₅₀	95.6 μM Compound: quercetin	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay	[PMID: 22989363]
RAW264.7	IC₅₀	16.4 μM Compound: Quercetin	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 24 hrs by Griess reaction analysis Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 24 hrs by Griess reaction analysis	[PMID: 23517145]
RAW264.7	IC₅₀	1.3 μM Compound: Quercetin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs	[PMID: 23540981]
RAW264.7	IC₅₀	>50 μM Compound: 15	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 18 hrs by griess reaction analysis	[PMID: 24679441]
RAW264.7	IC₅₀	2.9 μg/mL Compound: Quercetin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in nitric oxide production after 24 hrs by Griess method based ELISA Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in nitric oxide production after 24 hrs by Griess method based ELISA	[PMID: 25106885]
RAW264.7	IC₅₀	16.6 μM Compound: Quercetin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay	[PMID: 25245917]
RAW264.7	IC₅₀	1.8 μM Compound: Quercetin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay	[PMID: 26143931]
RAW264.7	CC₅₀	>50 μM Compound: Quercetin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26928174]
RAW264.7	IC₅₀	15 μM Compound: Quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by Griess assay	[PMID: 26928174]
RAW264.7	IC₅₀	15.9 μM Compound: Quercetin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 27177824]
RAW264.7	IC₅₀	4.41 μM Compound: Quercetin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay	[PMID: 28427811]
RAW264.7	IC₅₀	6.6 μM Compound: Quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced nitric oxide production Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced nitric oxide production	[PMID: 29280630]
RAW264.7	IC₅₀	15.1 μM Compound: Quercetin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay	[PMID: 32003565]
RAW264.7	IC₅₀	22.7 μM Compound: Quercetin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells by Griess reagent based assay	[PMID: 32118424]
RAW264.7	IC₅₀	4.53 μM Compound: Quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 32299661]
RAW264.7	IC₅₀	4.2 μM Compound: Quercetin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by alamarBlue assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by alamarBlue assay	[PMID: 32357011]
RAW264.7	IC₅₀	13.6 μM Compound: Quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production	[PMID: 33422907]
RAW264.7	IC₅₀	16.8 μM Compound: Quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production	[PMID: 33422907]
RAW264.7	IC₅₀	16.9 μM Compound: Quercetin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production	[PMID: 33422907]
RAW264.7	IC₅₀	13.6 μM Compound: 96; 99	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA	[PMID: 37683361]
RAW264.7	IC₅₀	14.16 μM Compound: 96; 99	Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production	[PMID: 37683361]
RAW264.7	IC₅₀	16.8 μM Compound: 96; 99	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA	[PMID: 37683361]
RAW264.7	IC₅₀	16.9 μM Compound: 96; 99	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-6 production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by ELISA	[PMID: 37683361]
RAW264.7	IC₅₀	22.5 μM Compound: 96; 99	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-stimulated IL-6 mRNA level incubated for 3 hrs by RT-qPCR analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-stimulated IL-6 mRNA level incubated for 3 hrs by RT-qPCR analysis	[PMID: 37683361]
RAW264.7	IC₅₀	35.45 μM Compound: 96; 99	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced IL-6 secretion after 24 hrs by ELISA method Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced IL-6 secretion after 24 hrs by ELISA method	[PMID: 37683361]
RBL-1	IC₅₀	0.3 μM Compound: Quercetin	In vitro inhibitory activity against RBL-1 5-LO In vitro inhibitory activity against RBL-1 5-LO	[PMID: 3820229]
RBL-1	IC₅₀	2.0 x 10^-7 M Compound: quercetin	In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined	[PMID: 8254620]
RF/6A	IC₅₀	40 μM Compound: Quercetin	Antimigratory activity in rhesus monkey RF/6A cells measured after 24 hrs by wound assay Antimigratory activity in rhesus monkey RF/6A cells measured after 24 hrs by wound assay	[PMID: 27015547]
RF/6A	IC₅₀	70 μM Compound: Quercetin	Antiproliferative activity in rhesus monkey RF/6A cells measured after 24 to 72 hrs by MTT assay Antiproliferative activity in rhesus monkey RF/6A cells measured after 24 to 72 hrs by MTT assay	[PMID: 27015547]
RS4-11	GI₅₀	21.6 μM Compound: 6	Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay	[PMID: 23411073]
Sf21	IC₅₀	28.6 μM Compound: 5	Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay	[PMID: 17378609]
SGC-7901	IC₅₀	7.878 μg/mL Compound: Compound 4	Cytotoxicity against human SGC7901 cells by MTT assay Cytotoxicity against human SGC7901 cells by MTT assay	[PMID: 25862199]
SH-SY5Y	IC₅₀	5.6 μM Compound: Quercetin	Neuroprotective activity against H202 induced oxidative stress in human SH-SY5Y cells measured after 1 hr by DCFH-DA staining based analysis Neuroprotective activity against H202 induced oxidative stress in human SH-SY5Y cells measured after 1 hr by DCFH-DA staining based analysis	[PMID: 37567058]
SH-SY5Y	IC₅₀	5.6 μM Compound: Quercetin	Antioxidant activity in human SH-5Y5Y cells assessed as reduction in H2O2-induced oxidation measured after 60 mins by DCFH-DA staining method Antioxidant activity in human SH-5Y5Y cells assessed as reduction in H2O2-induced oxidation measured after 60 mins by DCFH-DA staining method	[PMID: 39002183]
SK-MEL-2	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 28165740]
SK-MEL-2	IC₅₀	12 μM Compound: Quer	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SK-OV-3	IC₅₀	>10 μM Compound: 10	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 28165740]
SW1573	IC₅₀	>10 μg/mL Compound: 8	Cytotoxicity against human SW1573 cells after 3 days by MTT assay Cytotoxicity against human SW1573 cells after 3 days by MTT assay	[PMID: 11421746]
T47D	IC₅₀	11 μM Compound: Quer	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-251	IC₅₀	77.8 μM Compound: 51	Inhibition of cell proliferation of human U251 cells assessed as cell viability after 72 hrs by sulforhodamine B assay Inhibition of cell proliferation of human U251 cells assessed as cell viability after 72 hrs by sulforhodamine B assay	[PMID: 25442304]
U2OS	EC₅₀	5.93 μM Compound: Quercetin	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]
U-87MG ATCC	IC₅₀	23 μM Compound: Quer	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Vero	CC₅₀	151 μg/mL Compound: quercetin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 1338212]
Vero	IC₅₀	110 μg/mL Compound: 5	Cytotoxicity against african green monkey Vero cells by MTT assay Cytotoxicity against african green monkey Vero cells by MTT assay	[PMID: 18855442]
Vero	CC₅₀	3.32 mM Compound: 14	Cytotoxicity against african green monkey Vero cells incubated for 3 days Cytotoxicity against african green monkey Vero cells incubated for 3 days	[PMID: 32539378]
Vero C1008	CC₅₀	3.32 μM Compound: 41	Cytotoxicity against African green monkey Vero E6 cells by MTT assay Cytotoxicity against African green monkey Vero E6 cells by MTT assay	[PMID: 33486200]
Vero C1008	EC₅₀	83.4 μM Compound: 41	Antiviral activity against SARS-CoV pseudotyped virus infected in Vero E6 cells assessed as reduction in viral replication incubated for 2190 mins by ELISA assay Antiviral activity against SARS-CoV pseudotyped virus infected in Vero E6 cells assessed as reduction in viral replication incubated for 2190 mins by ELISA assay	[PMID: 33486200]
WiDr	IC₅₀	40.2 μM Compound: (2) quercetin	Cytotoxic effect on WiDr human colon cells Cytotoxic effect on WiDr human colon cells	[PMID: 8201603]
WM-115	IC₅₀	177.5 μM Compound: Quercetin	Cytotoxicity against human WM115 cells after 46 hrs by MTT assay Cytotoxicity against human WM115 cells after 46 hrs by MTT assay	[PMID: 23756061]

In Vitro

Quercetin is a type of plant-based chemical, or phytochemical, used as an ingredient in supplements, beverages or foods. In several studies, it may have anti-inflammatory and antioxidant properties, and it is being investigated for a wide range of potential health benefits. Quercetin is a PI3K inhibitor with IC₅₀ of 2.4-5.4 μM. Quercetin strongly abrogates PI3K and Src kinases, mildly inhibits Akt1/2, and slightly affected PKC, p38 and ERK1/2^[1]. Quercetin inhibits TNF-induced LDH% release, EC-dependent neutrophils adhesion to bovine pulmonary artery endothelial cells (BPAEC), and BPAEC DNA synthesis and proliferation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Combination of Quercetin (75 mg/kg) and 2-Methoxyestradiol enhances inhibition of human prostate cancer LNCaP and PC-3 cells xenograft tumor growth^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 117-39-5
Appearance Solid
Peso molecular 302.24
Fòrmula C₁₅H₁₀O₇
Color Light yellow to green yellow
SMILES

OC1=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1=O
Structure Classification
- Flavonoids
- Flavonols
Initial Source
- Plants
- other families
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (224)

All IHCWBCell Imaging/StainingRT-PCRIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cell Metab

Amygdala astrocyte senescence drives stress-induced anxiety and hyperglycemia. [Abstract]

2026 Jul 7;38(7):1385-1403.e10. PMID: 41935525
Cell Metab

Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy. [Abstract]

2025 Oct 24:S1550-4131(25)00395-X. PMID: 41138722
Immunity

p16High-expressing immune cells control disease tolerance as a defense and health span-extending strategy. [Abstract]

2026 Mar 26:S1074-7613(26)00083-X. PMID: 41895292
Nat Aging

Spatiotemporal transcriptomic changes of human ovarian aging and the regulatory role of FOXP1. [Abstract]

2024 Apr;4(4):527-545. PMID: 38594460

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Quercetin (10 μM; 24 h). mRNA relative expression of CDKN2A, IL-6 and IL-8 in si-FOXP1 COV434 treated with fisetin (F), quercetin (Q) and Dasatinib (D).

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Quercetin (10 μM; 24 h). Immunofluorescence staining of Ki67 upon administration of fisetin (F), quercetin (Q) and Dasatinib (D) in COV434 with knockdown of FOXP1.

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Quercetin (10 μM; 24 h). Immunofluorescence staining of γH2AX upon administration of fisetin (F), Quercetin (Q) and dasatinib (D) in COV434 with knockdown of FOXP1.

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h), or Dasatinib (100 nM, 24 h) delayed FOXP1 gene silencing-induced cellular senescence in COV434 cells.

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h) inhibited the FOXP1 silencing-induced increase in CDKN1A expression in COV434 cells.

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h) and Quercetin (10 μM, 24 h) reversed the decrease in COV434 cell proliferation induced by FOXP1 knockdown.

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Fisetin (10 μM, 24 h), Quercetin (10 μM, 24 h) delayed FOXP1 gene silencing in COV434 cells.

Quercetin purchased from MedChemExpress. Usage Cited in: Nat Aging. 2024 Apr;4(4):527-545. [Abstract]

Quercetin (10 μM, 24 h) but not Fisetin (10 μM, 24 h) decreased γH2AX levels in COV434 cells.
Cell Stem Cell

Senolytic-sensitive p16Ink4a+ fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2025 Dec 4;32(12):1869-1885.e8. PMID: 41187746
Adv Funct Mater

27 January 2022.
Autophagy

Trophoblast aging driven by IL33 deficiency elevates recurrent pregnancy loss risk through SNAP29 lactylation-mediated autophagy impairment. [Abstract]

2026 Jul;22(7):1679-1697. PMID: 41975562
Autophagy

Autophagic degradation of SQSTM1 enables fibroblast activation to accelerate wound healing. [Abstract]

2025 May 31:1-21. PMID: 40400126
Nat Commun

Systematic profiling reveals distinct senescence signatures and regulators across human brain cell types. [Abstract]

2025 Dec 11;16(1):11059. PMID: 41381419
Nat Commun

Tumor microenvironment-responsive engineered hybrid nanomedicine for photodynamic-immunotherapy via multi-pronged amplification of reactive oxygen species. [Abstract]

2025 Jan 6;16(1):424. PMID: 39762214
ACS Nano

Adverse Outcome Pathway-Based Strategies to Mitigate Ag2Se Quantum Dot-Induced Neurotoxicity. [Abstract]

2025 Mar 25;19(11):11029-11048. PMID: 40063898
Redox Biol

Quercetin improves retinal glycolysis to slow myopia progression through orchestrating the AKT/FOXO/HK2 axis. [Abstract]

2026 Mar 31:93:104139. PMID: 41980459
Redox Biol

Injectable ROS homeostasis protective hydrogel inhibiting microglial ferroptosis through the Nrf2/Slc7a11/Gpx4 to alleviate neuropathic pain and promote spinal cord injury repair. [Abstract]

2025 Aug 8:86:103816. PMID: 40795617
J Nanobiotechnology

Inverse-designed plasmonic biosensors with LSPR-SPP-wood anomaly coupling enhanced for biomolecular analysis. [Abstract]

2025 Dec 16;24(1):58. PMID: 41402825
J Nanobiotechnology

Quercetin combined with shTERT induces apoptosis in ovarian cancer via the P53/Bax pathway, and RGD-MSN/QR/shTERT nanoparticles enhance the therapeutic efficacy. [Abstract]

2025 Jul 22;23(1):536. PMID: 40696430
J Biomed Sci

Targeting a genomic RNA G-quadruplex of dengue virus with small molecules as an alternative to protein-targeted therapeutics. [Abstract]

2026 May 27;33(1):55. PMID: 42204560
J Biomed Sci

Targeting the G-quadruplex as a novel strategy for developing antibiotics against hypervirulent drug-resistant Staphylococcus aureus. [Abstract]

2025 Feb 5;32(1):15. PMID: 39905515
J Control Release

Quercetin liposomes conjugated with hyaluronidase: An efficient drug delivery system to block pancreatic cancer. [Abstract]

2025 Jun 10:382:113642. PMID: 40127723
Int J Biol Sci

Senescent renal tubular cells derived extracellular vesicles transported miR-20a and miR-21 induced macrophage-to-myofibroblast transition in renal fibrosis after ischemia reperfusion injury. [Abstract]

2025 Jan 6;21(3):940-954. PMID: 39897045
Phytomedicine

Cinchonain Ia inhibits uric acid reabsorption by binding to the TRP-459 residue of the GLUT9 protein. [Abstract]

2026 May 14:157:158292. PMID: 42176511
Phytomedicine

Multi-omics and machine learning reveal a critical mediator of PRKCA in quercetin-mediated protection against Sarcopenia. [Abstract]

2026 Jun:155:158121. PMID: 41936173
Phytomedicine

Quercetin targets IL6/JAK1/STAT3/MMP9 signaling to attenuate breast cancer progression in diabetic comorbidity: A multi-omics and experimental study. [Abstract]

2026 Mar:152:157819. PMID: 41638057
Phytomedicine

Study on the anti-liver cirrhosis of Fuzheng Huayu tablet : Targeting macrophage PPARα axis-fatty acid metabolic. [Abstract]

2025 Nov 22:150:157586. PMID: 41380414
Phytomedicine

Quercetin ameliorates doxorubicin-induced atrial fibrillation via EGFR-mediated restoration of autophagic flux. [Abstract]

2025 Oct 3:148:157357. PMID: 41056856
Phytomedicine

Guilu Erxian glue mitigates spermatogenesis dysfunction through HIF-1α/SLC7A11-mediated ferroptosis inhibition: An integrated metabolomics and network pharmacology study. [Abstract]

2025 Nov 25:148:157321. PMID: 41092579
Phytomedicine

CBX5 loss drives Pl3Kδ inhibitor resistance in mantle cell lymphoma and propolis restores sensitivity by inducing CBX5-mediated ferroptosis. [Abstract]

2025 May 27:143:156911. PMID: 40466505
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Herbal-based Xuebijing injection ameliorated vascular endothelial dysfunction via inhibiting ACLY/MYB/RIG-I axis in sepsis-associated lung injury. [Abstract]

2025 May:140:156573. PMID: 40088739
EBioMedicine

PPAR-γ suppresses macrophage senescence and allergic airway inflammation through controlling lipid metabolic pathways. [Abstract]

2026 Apr:126:106226. PMID: 41864062
Adv Healthc Mater

Liposomal Quercetin-Loaded Biomimetic Scaffolds Manage Mechanical Overload in Maxillofacial Regeneration by Stabilizing the β-Actin/YAP Mechanosensing Axis. [Abstract]

2026 Jun;15(22):e05818. PMID: 42027072
Adv Healthc Mater

Macrophage Membrane-Cloaked, ROS-Triggered Quercetin Nanocarriers Target Ovarian Lesions to Treat Polycystic Ovary Syndrome. [Abstract]

2026 Feb 21:e05171. PMID: 41721609
Mater Today Bio

Quercetin-loaded exosomes delivery system prevents myopia progression by targeting endoplasmic reticulum stress and ferroptosis in scleral fibroblasts. [Abstract]

2025 May 28:32:101896. PMID: 40520556
Mater Today Bio

Enhanced hydrogel loading of quercetin-loaded hollow mesoporous cerium dioxide nanoparticles for skin flap survival. [Abstract]

2024 Dec 28:30:101432. PMID: 39839491
J Hazard Mater

Ammonia-induced exosomal miRNA disrupts autophagy and promotes lung injury: Therapeutic potential of natural compounds. [Abstract]

2026 Mar 15:506:141417. PMID: 41775203
J Hazard Mater

PFPeA exposure drives hepatoxicity and liver fibrosis via oxidative stress/Wnt5a-induced hepatocyte senescence. [Abstract]

2026 Feb 1:503:141085. PMID: 41529635
Cell Death Discov

Sympathetic nerve inhibition enhances calvarial bone repair via senescent macrophage-induced osteogenesis and angiogenesis. [Abstract]

2025 Dec 10;11(1):564. PMID: 41372112
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576
J Crohns Colitis

Drug repurposing approach for the discovery of therapeutic agents for Crohn's disease-associated intestinal fibrosis. [Abstract]

2025 Sep 28;19(9):jjaf137. PMID: 41027688
Osteoarthritis Cartilage

Senolytic agent Quercetin ameliorates intervertebral disc degeneration via the Nrf2/NF-κB axis. [Abstract]

2021 Mar;29(3):413-422. PMID: 33242601
J Hazard Mater Lett

2025 Nov.
Food Res Int

Glycyrrhiza uralensis Fisch: A novel source of analgesic activity through NaV1.8 sodium channel modulation. [Abstract]

2025 Dec;222(Pt 1):117620. PMID: 41267240
Int J Biol Macromol

Quercetin-loaded cellulose nanocrystals for targeted redox modulation and inflammation control in rosacea therapy via the SOD2-NF-κB pathway. [Abstract]

2026 Jun:365:152440. PMID: 42106045
New Phytol

Transcription factor SlJIG orchestrates multi-layer defense in tomato against the invasive pest Phthorimaea absoluta. [Abstract]

2025 Dec 7. PMID: 41355216
Int J Nanomedicine

Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-Resistant Enterobacteriaceae. [Abstract]

2025 Aug 25:20:10255-10277. PMID: 40896802
Int J Biol Macromol

Integrating network pharmacology to investigate the mechanism of quercetin's action through AKT inhibition in co-expressed genes associated with polycystic ovary syndrome and endometrial cancer. [Abstract]

2025 Jan 5:139468. PMID: 39765297
Int J Mol Med

Quercetin ameliorates senescence and promotes osteogenesis of BMSCs by suppressing the repetitive element‑triggered RNA sensing pathway. [Abstract]

2025 Jan;55(1):4. PMID: 39450556
Int J Mol Med

Quercetin ameliorates ferroptosis of rat cardiomyocytes via activation of the SIRT1/p53/SLC7A11 signaling pathway to alleviate sepsis‑induced cardiomyopathy. [Abstract]

2023 Dec;52(6):116. PMID: 37859612
Antioxidants (Basel)

Bioaffinity Ultrafiltration Combined with HPLC-ESI-qTOF-MS/MS for Screening Potential Bioactive Components from the Stems of Dendrobium fimbriatum and In Silico Analysis. [Abstract]

2024 Jul 29;13(8):918. PMID: 39199164
Antioxidants (Basel)

Antioxidant, Anti-α-Glucosidase, Antityrosinase, and Anti-Inflammatory Activities of Bioactive Components from Morus alba. [Abstract]

2022 Nov 11;11(11):2222. PMID: 36421408
Cell Mol Gastroenterol Hepatol

Mannan-Binding Lectin via Interaction With Cell Surface Calreticulin Promotes Senescence of Activated Hepatic Stellate Cells to Limit Liver Fibrosis Progression. [Abstract]

2022 Apr 2;14(1):75-99. PMID: 35381393
Antioxidants (Basel)

Comparison of Various Solvent Extracts and Major Bioactive Components from Unsalt-Fried and Salt-Fried Rhizomes of Anemarrhena asphodeloides for Antioxidant, Anti-α-Glucosidase, and Anti-Acetylcholinesterase Activities. [Abstract]

2022 Feb 14;11(2):385. PMID: 35204266
Phytother Res

Quercetin Overcomes Cisplatin Resistance by Inducing Ferroptosis via the DDB2-AS1/miR-4728-5p/p53 Axis. [Abstract]

2026 Mar;40(3):1230-1251. PMID: 41562315
Free Radic Biol Med

Mechanisms and targeted intervention of mitochondria-dependent ferroptosis and abnormal ductular reaction caused by benzo(a)pyrene. [Abstract]

2025 Oct 1:241:543-555. PMID: 41043626
Free Radic Biol Med

Quercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2/p-DRP1 and NRF2/GPX4 Axes. [Abstract]

2024 Mar:213:150-163. PMID: 38190923
J Anim Sci Biotechnol

Quercetin mitigates iron-induced cell death in chicken granulosa cell. [Abstract]

2024 Dec 8;15(1):168. PMID: 39645563
J Anim Sci Biotechnol

Quercetin ameliorates oxidative stress-induced apoptosis of granulosa cells in dairy cow follicular cysts by activating autophagy via the SIRT1/ROS/AMPK signaling pathway. [Abstract]

2024 Sep 5;15(1):119. PMID: 39232832
Am J Chin Med

Mechanism of Quercetin and Luteolin on Colon Cancer Metastasis: Network Pharmacological Study and Experimental Validation. [Abstract]

2026 Apr 30:1-20. PMID: 42057261
Am J Chin Med

Quercetin Alleviates Endothelial Dysfunction in Atherosclerosis by Inhibiting Ferroptosis Through PACS2/HMOX-1 Pathway. [Abstract]

2026;54(2):603-625. PMID: 41692703
Am J Chin Med

Identification of Flavonoid Compounds in Treating Alzheimer's Disease Based on Network Medicine Framework Strategy. [Abstract]

2025 Aug 30:1-32. PMID: 40884807
ACS Appl Mater Interfaces

Extracellular Matrix-Mimicking Hydrogel with Angiogenic and Immunomodulatory Properties Accelerates Healing of Diabetic Wounds by Promoting Autophagy. [Abstract]

2025 Jan 22;17(3):4608-4625. PMID: 39800939
Aging Cell

2026 Jan 20;25(2):e70352.
Chin Med

Unveiling medication patterns in traditional Chinese medicine for the prevention of colorectal cancer recurrence: from potential combinations to validation of components and targets. [Abstract]

2026 Jun 4;21(1):160. PMID: 42243877
Chin Med

The combination of Schisandrin C and Luteolin synergistically attenuates hepatitis B virus infection via repressing HBV replication and promoting cGAS-STING pathway activation in macrophages. [Abstract]

2024 Mar 18;19(1):48. PMID: 38500179
Environ Pollut

Quercetin antagonizes imidacloprid-induced mitochondrial apoptosis through PTEN/PI3K/AKT in grass carp hepatocytes. [Abstract]

2021 Dec 1:290:118036. PMID: 34488159
Front Immunol

Miquelianin inhibits IAV infection via the MAPK signaling pathway both in vitro and in vivo. [Abstract]

2025 Mar 17:16:1532336. PMID: 40165966

Quercetin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2025 Mar 17:16:1532336. [Abstract]

After infection of MDCK cells with H1N1-UI182 at an MOI of 0.01, the cells were treated with Quercetin (10 µM), Taxifolin (50 µM), Miquelianin (100 µM), and Baloxavir (10 µM) for 48 h. Nuclei were stained with DAPI, and infected cells were detected by NP-specific immunofluorescence staining (scale bar: 100 µm).
Mol Cancer Ther

Harnessing senolytics and PARP inhibition to expand the antitumor activity of CDK4/6 inhibitors in prostate cancer. [Abstract]

2025 Jul 2. PMID: 40601842
Pharmaceutics

Plasma Protein Binding, Biostability, Metabolite Profiling, and CYP450 Phenotype of TPB15 Across Different Species: A Novel Smoothened Inhibitor for TNBC Therapy. [Abstract]

2025 Mar 26;17(4):423. PMID: 40284418
J Ethnopharmacol

Simo Tang mitigates mitochondria-dependent apoptosis via PI3K/AKT pathway activation in Chronic atrophic gastritis. [Abstract]

2026 May 23:363:121417. PMID: 41765119
J Ethnopharmacol

Integrated metabolomics and proteomics analysis elucidated the therapeutic effect of Huangkui Capsule on tacrolimus-induced chronic nephrotoxicity in rats. [Abstract]

2026 Apr 6:360:121196. PMID: 41534748
JCI Insight

Neutrophil extracellular traps potentiate effector T cells via endothelial senescence in uveitis. [Abstract]

2025 Jan 23;10(2):e180248. PMID: 39846254
J Ethnopharmacol

Integrating UHPLC-Q-TOF-MS/MS, network pharmacology, bioinformatics and experimental validation to uncover the anti-cancer mechanisms of TiaoPi AnChang decoction in colorectal cancer. [Abstract]

2024 Jul 11:118576. PMID: 39002822
J Ethnopharmacol

Quantitative proteomics reveal the protective effects of EDS against osteoarthritis via attenuating inflammation and modulating immune response. [Abstract]

2021 May 10:271:113780. PMID: 33421600
J Agric Food Chem

Transcription Repressor SsGATA2 Regulates Broad-Spectrum Resistance to Fungicides and Pathogenicity in Sclerotinia sclerotiorum. [Abstract]

2025 Jul 9;73(27):16787-16803. PMID: 40558024
J Agric Food Chem

Protective Mechanisms of Various Active Substances on Cell DNA Damage and Apoptosis Induced by Deoxynivalenol. [Abstract]

2024 Mar 27;72(12):6651-6659. PMID: 38501756
J Agric Food Chem

Quercetin Alleviates Acrylamide-Induced Liver Injury by Inhibiting Autophagy-Dependent Ferroptosis. [Abstract]

2023 May 17;71(19):7427-7439. PMID: 37134181
J Agric Food Chem

Chemoproteomic Profiling of Cobalamin-Independent Methionine Synthases in Plants with a Covalent Probe. [Abstract]

2020 Jul 29;68(30):8050-8056. PMID: 32618189
Eur J Med Chem

Marine derived xyloketal derivatives exhibit anti-stress and anti-ageing effects through HSF pathway in Caenorhabditis elegans. [Abstract]

2018 Mar 25:148:63-72. PMID: 29454917
Ecotoxicol Environ Saf

FOXP1 deficiency exacerbates cellular senescence in PM2.5-induced renal injury. [Abstract]

2026 Apr 1:314:120071. PMID: 41916119
CNS Neurosci Ther

ShenQi DiHuang Decoction (SQDHD) Ameliorates Neuroinflammation and Neuropsychiatric Manifestations in Pristane Induced Lupus Mice via Blocking JAK1-STAT3 Pathway. [Abstract]

2026 Mar;32(3):e70814. PMID: 41795136
Ecotoxicol Environ Saf

Bisphenol S decreased lifespan and healthspan via insulin/IGF-1-like signaling-against mitochondrial stress in Caenorhabditis elegans. [Abstract]

2024 Oct 15:285:117136. PMID: 39353373
Biochem Pharmacol

Quercetin ameliorates SIRT1-mediated oxidative stress and inflammation to attenuate ciliary muscle remodeling in experimental myopia. [Abstract]

2026 Mar:245:117698. PMID: 41519402
J Environ Sci

2025 Sep 20.
Ind Crops Prod

2026 May 8;246:123392.
Ind Crops Prod

2026 Jan 22;241:122697.
Ind Crops Prod

2025 Dec 11;239:122458.
Life Sci

Quercetin alleviates kidney fibrosis by reducing renal tubular epithelial cell senescence through the SIRT1/PINK1/mitophagy axis. [Abstract]

2020 Sep 15;257:118116. PMID: 32702447

Quercetin purchased from MedChemExpress. Usage Cited in: Life Sci. 2020 Sep 15;257:118116. [Abstract]

NRK-52E cells are treated with Quercetin (Quer, 20 μM) for 2 h prior to incubation with AngII (100 nM) for another 72 h. The expression of p21 and p16ink4a are detected using Western blotting, and quantitative analyses are performed.
Inflammopharmacology

Vitexin mitigates oxidative stress, mitochondrial damage, pyroptosis and regulates small nucleolar RNA host gene 1/DNA methyltransferase 1/microRNA-495 axis in sepsis-associated acute lung injury. [Abstract]

2025 Mar;33(3):1435-1454. PMID: 39641834
Inflammopharmacology

Quercetin alleviates neonatal hypoxic-ischaemic brain injury by rebalancing microglial M1/M2 polarization through silent information regulator 1/ high mobility group box-1 signalling. [Abstract]

2025 Feb;33(2):865-883. PMID: 39565473
Bioresour Bioprocess

Assessing multi-target antiviral and antioxidant activities of natural compounds against SARS-CoV-2: an integrated in vitro and in silico study. [Abstract]

2024 Nov 27;11(1):108. PMID: 39604740
Food Biosci

2026 Apr 27;80:108990.
Inflamm Res

Quercetin alleviates neonatal hypoxic-ischemic brain injury by inhibiting microglia-derived oxidative stress and TLR4-mediated inflammation. [Abstract]

2020 Dec;69(12):1201-1213. PMID: 32944799
Drug Des Devel Ther

Network Pharmacology Approach to Unveiling the Mechanism of Wolfberry Mulberry Raspberry Decoction in the Treatment of Sepsis-Induced Myocardial Dysfunction. [Abstract]

2025 Jun 20:19:5293-5310. PMID: 40557053
Eur J Pharmacol

Targeting FoxO1-STX17-mediated autophagic flux: Quercetin's therapeutic mechanism in diabetic nephropathy. [Abstract]

2025 Dec 5:1008:178309. PMID: 41207350
Respir Res

Exploring the mechanism of Lianhuaqingwen (LHQW) in treating chronic bronchitis based on network pharmacology and experimental validation. [Abstract]

2024 Aug 2;25(1):294. PMID: 39095732
Int Immunopharmacol

Quercetin regulates lipid metabolism and inflammatory microenvironment of microglia after spinal cord injury through activating the butyrate-FFAR2/AMPK/TFEB gut-brain axis signaling pathway. [Abstract]

2026 Sep 1:184:116928. PMID: 42217340
Int J Mol Sci

Multi-Omics and Functional Validation Identify a Quercetin-SLC15A2 Axis That Mediates the Anti-Fibrotic Effect of Shen-Kang Recipe in Diabetic Kidney Disease. [Abstract]

2026 Apr 5;27(7):3291. PMID: 41977470
Int Immunopharmacol

Quercetin alleviates LPS-induced inflammation and immunosuppression in broiler spleen via regulating the mtDNA/cGAS/STING axis. [Abstract]

2026 May 1:176:116482. PMID: 41797087
Int Immunopharmacol

METTL14 deficiency impairs chondrogenic differentiation via m6A-dependent TRAF4 mRNA regulation in Kashin-Beck disease. [Abstract]

2026 Apr 15:175:116409. PMID: 41763167
Int Immunopharmacol

Quercetin down-regulates MCP-1 expression in autoimmune myocarditis via ERK1/2-C/EBPβ pathway: An integrative approach using network pharmacology and experimental models. [Abstract]

2025 Mar 29:154:114559. PMID: 40158430
Int Immunopharmacol

Quercetin Protects against Silicon dioxide Particles-induced spleen ZBP1-Mediated PANoptosis by regulating the Nrf2/Drp1/mtDNA axis. [Abstract]

2024 Nov 2;143(Pt 3):113546. PMID: 39488923
Int Immunopharmacol

Quercetin-primed BMSC-derived extracellular vesicles ameliorate chronic liver damage through miR-136-5p and GNAS/STAT3 signaling pathways. [Abstract]

2024 Sep 27;142(Pt B):113162. PMID: 39340996
Int J Mol Sci

Quercetin Modulates Ferroptosis via the SIRT1/Nrf-2/HO-1 Pathway and Attenuates Cartilage Destruction in an Osteoarthritis Rat Model. [Abstract]

2024 Jul 7;25(13):7461. PMID: 39000568
Int J Mol Sci

The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs. [Abstract]

2024 Apr 4;25(7):4031. PMID: 38612842
Glia

Geranylgeranylacetone-Induced HSP70 Modulates AQP4 Trafficking via SNX27-Retromer to Alleviate Retinal Ischemia/Reperfusion Injury. [Abstract]

2026 Aug;74(8):e70184. PMID: 42289963
Invest Ophthalmol Vis Sci

Quercetin Alleviates Scleral Remodeling Through Inhibiting the PERK-EIF2α Axis in Experiment Myopia. [Abstract]

2024 Nov 4;65(13):11. PMID: 39504054
J Periodontal Res

Quercetin promotes autophagy to alleviate cigarette smoke-related periodontitis. [Abstract]

2023 Oct;58(5):1082-1095. PMID: 37533377
ACS Omega

Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification. [Abstract]

2025 Apr 29;10(18):19019-19032. PMID: 40385224
Chem Biol Interact

A water-soluble preparation for intravenous administration of isorhamnetin and its pharmacokinetics in rats. [Abstract]

2024 May 19:396:111064. PMID: 38768772
Plant Methods

Carbon dioxide expanded liquid: an effective solvent for the extraction of quercetin from South African medicinal plants. [Abstract]

2022 Jun 23;18(1):87. PMID: 35739596
Clin Exp Ophthalmol

Novel Insight of Posterior Capsule Opacification: The Role of Lens Epithelial Cell Senescence. [Abstract]

2025 Jul 14. PMID: 40660668
Tissue Eng Regen Med

Exosomes Derived from Rejuvenated Stem Cells Inactivate NLRP3 Inflammasome and Pyroptosis of Nucleus Pulposus Cells via the Transfer of Antioxidants. [Abstract]

2024 Oct;21(7):1061-1077. PMID: 39060654
Molecules

New Triterpenoids and Anti-Inflammatory Constituents from Glinus oppositifolius. [Abstract]

2023 Mar 23;28(7):2903. PMID: 37049664
Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370
Mol Med Rep

Exploring the role of cytochrome P450 family 1 subfamily B member 1 and quercetin in modulating neuropathic pain after spinal cord injury. [Abstract]

2026 Jan;33(1):7. PMID: 41104896
Food Sci Nutr

Quercetin Improves Lipopolysaccharide-Induced Septic Liver Injury by Inhibiting the Activation of ROCK/NF-κB/NLRP3 Pathway. [Abstract]

2025 Aug 4;13(8):e70757. PMID: 40766788
Mol Med Rep

Quercetin attenuates the symptoms of osteoarthritis in vitro and in vivo by suppressing ferroptosis via activation of AMPK/Nrf2/Gpx4 signaling. [Abstract]

2025 Mar;31(3):60. PMID: 39717946
Mol Med Rep

Tea seed saponin‑reduced extract ameliorates palmitic acid‑induced insulin resistance in HepG2 cells. [Abstract]

2024 Feb;29(2):26. PMID: 38099345
Sci Rep

Quercetin modulates mast cell activation and the IL-33/ST2/NF-κB axis in allergic rhinitis. [Abstract]

2026 Jun 14. PMID: 42289577
Sci Rep

Synthesis and performance optimization of multi-bioactive compound-loaded nanocarriers for antimicrobial applications. [Abstract]

2025 Nov 21;15(1):41324. PMID: 41271794
Sci Rep

IGFBP3-mediated effects of an effective combination therapy on HCC. [Abstract]

2025 Aug 19;15(1):28604. PMID: 40830349
APL Bioeng

Quercetin targets the Ccl4-Ccr5 axis to relieve neuropathic pain after spinal cord injury. [Abstract]

2025 Jul 24;9(3):036108. PMID: 40717840
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
Sci Rep

Investigation of Scutellaria Barbata's immunological mechanism against thyroid cancer using network pharmacology and experimental validation. [Abstract]

2025 Jan 20;15(1):2490. PMID: 39833432
Sci Rep

Network pharmacological prediction of the mechanism of action of Shen-Zhu-Lian-Bai Decoction in the treatment of ulcerative colitis. [Abstract]

2024 Jun 20;14(1):14183. PMID: 38902425
World J Stem Cells

Quercetin ameliorates oxidative stress-induced senescence in rat nucleus pulposus-derived mesenchymal stem cells via the miR-34a-5p/SIRT1 axis. [Abstract]

2023 Aug 26;15(8):842-865. PMID: 37700818
Spectrochim Acta A Mol Biomol Spectrosc

A portable sensing platform enabled by permanganate-peroxide coupling for time-resolved analysis of xanthine oxidase activity in circulating tumor cells. [Abstract]

2026 Jun 25;363(Pt 1):128317. PMID: 42364482
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045
Eur J Med Res

Quercetin inhibits the progression of endometrial HEC-1-A cells by regulating ferroptosis-a preliminary study. [Abstract]

2022 Dec 15;27(1):292. PMID: 36522794
Comput Struct Biotechnol J

Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. [Abstract]

2021 Oct 1:19:5568-5577. PMID: 34712400
Rheumatology (Oxford)

Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]

2025 Aug 13:keaf437. PMID: 40802538
J Inflamm Res

Chinese Herbal Medicine Suyin Detoxification Granule Inhibits Pyroptosis and Epithelial-Mesenchymal Transition by Downregulating MAVS/NLRP3 to Alleviate Renal Injury. [Abstract]

2021 Dec 7;14:6601-6618. PMID: 34908861
Biomedicines

Integrated Network Pharmacology, Molecular Docking and Experimental Validation Reveal That Quercetin Suppresses Clear Cell Renal Cell Carcinoma via MMP9-Associated Macrophage Polarization. [Abstract]

2026 Apr 16;14(4):904. PMID: 42072446
iScience

Quercetin potentially suppresses HBV activity through targeting the RIG-I/MAVS pathway. [Abstract]

2026 Apr 12;29(5):115704. PMID: 42111216
Mol Nutr Food Res

Flavonoid Polyphenols as Therapeutic Agents for Fatty Liver Disease: Mechanisms, Microbiome Interactions, and Metabolic Insights. [Abstract]

2025 Jun 16:e70144. PMID: 40522112
BMC Complement Med Ther

Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer. [Abstract]

2023 Dec 1;23(1):433. PMID: 38041080
BMC Complement Med Ther

Centipeda minima active components and mechanisms in lung cancer. [Abstract]

2023 Mar 23;23(1):89. PMID: 36959600
Mol Divers

Investigating the molecular mechanism of epimedium herb in treating rheumatoid arthritis through network pharmacology, molecular docking, and experimental validation. [Abstract]

2025 Jan 16. PMID: 39821498
Biology (Basel)

Antibacterial, Antibiofilm, and Wound Healing Activities of Rutin and Quercetin and Their Interaction with Gentamicin on Excision Wounds in Diabetic Mice. [Abstract]

2024 Aug 29;13(9):676. PMID: 39336103
Front Biosci (Landmark Ed)

Quercetin Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells. [Abstract]

2026 Mar 31;31(4):47715. PMID: 42052849
Front Biosci (Landmark Ed)

Dual Role of Quercetin in Promoting Early Wound Healing via Inhibiting Inflammatory Factors and Attenuating Scar Formation by Suppressing Myofibroblast Differentiation. [Abstract]

2025 Jul 25;30(7):40077. PMID: 40765355
Naunyn Schmiedebergs Arch Pharmacol

Integrated bioinformatics, single-cell analysis, and experimental validation identify quercetin as a potential therapeutic candidate for intervertebral disc degeneration. [Abstract]

2026 Jun 22. PMID: 42329412
Naunyn Schmiedebergs Arch Pharmacol

Quercetin inhibits glycolysis and tumor progression in a cell line-dependent manner, involving PI3K/AKT signaling predominantly in HOS cells. [Abstract]

2026 Jan 29. PMID: 41609854
Naunyn Schmiedebergs Arch Pharmacol

Quercetin as a promising HIS-C inhibitor and novel therapeutic against antibacterial drug-resistant Acinetobacter baumannii: in vitro and in silico insights. [Abstract]

2025 Nov 20. PMID: 41263994
Naunyn Schmiedebergs Arch Pharmacol

The immunotherapy mechanism of Hedyotis Diffusae Herba in treating liver cancer: a study based on network pharmacology, bioinformatics, and experimental validation. [Abstract]

2025 Jan;398(1):951-965. PMID: 39093467
Naunyn Schmiedebergs Arch Pharmacol

Exploring the immunological mechanism of Houttuynia cordata in the treatment of colorectal cancer through combined network pharmacology and experimental validation. [Abstract]

2024 Nov;397(11):9095-9110. PMID: 38888753
Naunyn Schmiedebergs Arch Pharmacol

Mechanism of Sophorae Flavescentis Radix against ovarian cancer via new pharmacology, molecular docking, and experimental verification. [Abstract]

2024 Sep;397(9):6837-6850. PMID: 38561549
Naunyn Schmiedebergs Arch Pharmacol

Exploring the mechanism by which quercetin re-sensitizes breast cancer to paclitaxel: network pharmacology, molecular docking, and experimental verification. [Abstract]

2023 Nov;396(11):3045-3059. PMID: 37148401
J Funct Foods

2024 Aug.
J Biomed Mater Res A

Decellularised Cartilage-Based Hydrogels Functionalised With Chondroitin Sulphate and Quercetin: The Impact on Chondrogenesis. [Abstract]

2025 Oct;113(10):e37999. PMID: 41039807
Pathol Res Pract

Integrated multi-omics and experimental validation reveal DYNLT3 as a tumor suppressor regulated by quercetin in lung squamous cell carcinoma. [Abstract]

2026 Sep:285:156545. PMID: 42166936
J Med Virol

Quercetin Interrupts the SIRT3/ROS/NF-κB/SPI1 Feedback Loop to Ameliorate Microglia-Mediated HIV-1 Tat Neurotoxicity. [Abstract]

2026 Apr;98(4):e70906. PMID: 41964421
Breast Cancer

Quercetin Promote the Chemosensitivity in Organoids Derived from Patients with Breast Cancer. [Abstract]

2024 Dec 20:16:993-1004. PMID: 39720358
Stem Cells Int

2026 Mar 30;2026(1):3690230.
J Biochem Mol Toxicol

Quercetin Attenuates Cadmium-Induced Acute Lung Injury via Nrf2-Keap1 Pathway Activation. [Abstract]

2025 Sep;39(9):e70463. PMID: 40874705
Plant Foods Hum Nutr

Quercetin, Engelitin and Caffeic Acid of Smilax china L. Polyphenols, Stimulate 3T3-L1 Adipocytes to Brown-like Adipocytes Via β3-AR/AMPK Signaling Pathway. [Abstract]

2022 Dec;77(4):529-537. PMID: 35986845
Genomics

Transcriptomics and metabolomics reveal the induction of flavonoid biosynthesis pathway in the interaction of Stylosanthes-Colletotrichum gloeosporioides. [Abstract]

2021 Jul;113(4):2702-2716. PMID: 34111523
J Cosmet Dermatol

Network Pharmacology Approach to Explore the Skin-Lightening Compounds and Potential Mechanisms of Chinese Herbal Medicines. [Abstract]

2025 Dec;24(12):e70562. PMID: 41351313
Diabetes Metab Syndr Obes

A Network Pharmacology-Based Investigation into the Mechanism of Quercetin Combined with Rosuvastatin in Delaying Diabetic Nephropathy via Inhibiting NRK-52E Cell Ferroptosis. [Abstract]

2025 Aug 5:18:2681-2694. PMID: 40785752
Exp Cell Res

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]

2020 Aug 1;393(1):112054. PMID: 32376287
Front Oncol

Salvia chinensis Benth Inhibits Triple-Negative Breast Cancer Progression by Inducing the DNA Damage Pathway. [Abstract]

2022 Aug 10;12:882784. PMID: 36033499
Virus Res

Quercetin as an antiviral agent inhibits the Pseudorabies virus in vitro and in vivo. [Abstract]

2021 Nov:305:198556. PMID: 34492238
Chem Biol Drug Des

Quercetin alleviates hyperoxia-induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK/PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations. [Abstract]

2024 Apr;103(4):e14520. PMID: 38570710
Infect Drug Resist

Investigating the Therapeutic Mechanisms of Honeysuckle (China) in Sepsis Through Network Pharmacology and Experimental Validation. [Abstract]

2025 Jul 3:18:3257-3277. PMID: 40630747
Food Chem Toxicol

Ferroptosis is involved in quercetin-mediated alleviation of Ochratoxin A-induced kidney damage. [Abstract]

2024 Jul 23:114877. PMID: 39053875
Chin J Integr Med

Quercetin Confers Protection against Sepsis-Related Acute Respiratory Distress Syndrome by Suppressing ROS/p38 MAPK Pathway. [Abstract]

2025 Jun 24. PMID: 40553253
Exp Eye Res

Geranylgeranylacetone-induced heat shock protein70 expression reduces retinal ischemia-reperfusion injury through PI3K/AKT/mTOR signaling. [Abstract]

2023 Apr:229:109416. PMID: 36801237
Immunobiology

Quercetin acts as a novel anti-cancer drug to suppress cancer aggressiveness and cisplatin-resistance in nasopharyngeal carcinoma (NPC) through regulating the yes-associated protein/Hippo signaling pathway. [Abstract]

2023 Mar;228(2):152324. PMID: 36608594
Chin J Integr Med

Active Ingredients of Reduning Injections Maintain High Potency against SARS-CoV-2 Variants. [Abstract]

2023 Mar;29(3):205-212. PMID: 36374439
Exp Eye Res

Elimination of senescent cells inhibits epithelial-mesenchymal transition of retinal pigment epithelial cells. [Abstract]

2022 Oct:223:109207. PMID: 35926646
Gerontology

Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-κB Axis in a YTHDF2-Dependent Manner. [Abstract]

2022;68(8):920-934. PMID: 35468611
Cell Biochem Biophys

Suyin Detoxification Prescription Regulates the Klotho and ERK/NF-κB Signaling Pathways to Alleviate Renal Injury. [Abstract]

2025 Feb 18. PMID: 39966333
Front Cardiovasc Med

Exploring the Mechanism of Hawthorn Leaves Against Coronary Heart Disease Using Network Pharmacology and Molecular Docking. [Abstract]

2022 Jun 16:9:804801. PMID: 35783840
Insects

Utilization of Quercetin as an Oviposition Stimulant by Lab-Cultured Coleomegillamaculata in the Presence of Conspecifics and a Tissue Substrate. [Abstract]

2018 Jun 29;9(3). pii: E77. PMID: 29966274
Theriogenology

The role of β-catenin in ovarian differentiation by upregulation cyp19a1a in a natural triploid teleost, Qi River crucian carp (Carassius auratus). [Abstract]

2025 Dec 10:252:117782. PMID: 41411765
Behav Brain Res

Combined use of dasatinib and quercetin alleviates overtraining-induced deficits in learning and memory through eliminating senescent cells and reducing apoptotic cells in rat hippocampus. [Abstract]

2023 Feb 25:440:114260. PMID: 36535433
Biomed Res Int

Network-Based Pharmacology and Bioinformatics Study on the Mechanism of Action of Gujiansan in the Treatment of Steroid-Induced Avascular Necrosis of the Femoral Head. [Abstract]

2022 Jul 23:2022:8080679. PMID: 35915795
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
J Pharmacol Sci

2026 Feb 3.
Toxicon

Quercetin induces immunogenic cell death against gastric cancer by targeting NR3C1. [Abstract]

2025 Oct:265:108477. PMID: 40617261
PLoS One

Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis. [Abstract]

2024 Jul 11;19(7):e0305612. PMID: 38990915
Transl Vis Sci Technol

Targeting the Hedgehog Signaling Pathway in the Retina Using Quercetin-Loaded Lipid Nanoparticles for Myopia Control. [Abstract]

2026 Apr 6;15(4):3. PMID: 41944664
Toxicol In Vitro

Inhibitory potential of phytochemicals on species-specific breast cancer resistance protein transport activity. [Abstract]

2025 Dec:109:106128. PMID: 40796067
Cryobiology

Quercetin enhances the cold storage effect on human umbilical cord mesenchymal stem cells in Celsior solution. [Abstract]

2025 Sep:120:105299. PMID: 40896914
Thorac Cancer

Quercetin induces pro-apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell lines A549 and H1299 in vitro. [Abstract]

2021 May;12(9):1415-1422. PMID: 33709560
Biochem Biophys Res Commun

Integrative transcriptomics and single-cell analysis unravel the senescence-reversing mechanism of quercetin in osteoarthritic chondrocytes. [Abstract]

2026 Jun 25:819:153831. PMID: 42030882
Cancer Rep (Hoboken)

Unraveling the Anti-Tumor Effects and Molecular Mechanisms of Hairyvein Agrimonia Herb in Gastric Cancer Through Network Pharmacology and Experimental Validation. [Abstract]

2025 May;8(5):e70169. PMID: 40391580
Cancer Rep (Hoboken)

Quercetin Induces Apoptosis Through Downregulating P4HA2 and Inhibiting the PI3K/Akt/mTOR Axis in Hepatocellular Carcinoma Cells: An In Vitro Study. [Abstract]

2025 May;8(5):e70220. PMID: 40347062
Biochem Biophys Res Commun

The role of quercetin in modulating lipid metabolism and enhancing chemotherapy via the STAT3-CPT1B pathway in pancreatic cancer. [Abstract]

2025 May 20:772:152033. PMID: 40412371
J Food Biochem

2024 Aug 28.
Biochem Syst Ecol

2025 Oct.
Exp Ther Med

Quercetin suppresses apoptosis of chondrocytes induced by IL-1β via inactivation of p38 MAPK signaling pathway. [Abstract]

2021 May;21(5):468. PMID: 33767763
J Herb Med

2025 Aug 20.
Medicine

Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer. [Abstract]

2023 Oct 13;102(41):e35384. PMID: 37832105
Biol Pharm Bull

He-Wei-Decoction Ameliorates Chronic Atrophic Gastritis via Modulation of the TLR4/NF-κB Signaling Pathway. [Abstract]

2025;48(10):1514-1525. PMID: 41083380
bioRxiv

2026 Jun 20.
Res Sq

2025 Nov 12.
Chemistry of Plant Raw Material

2025.
SSRN

2025 Jul 8.
Res Sq

2025 Jul 17.
Regulatory Research and Medicine Evaluation

2025.
bioRxiv

2025 Jun 27.
Research Square Print

2025 May 28.
SSRN

2025 May 7.
bioRxiv

Regulatory Network Inference of Induced Senescent Midbrain Cell Types Reveals Cell Type-Specific Senescence-Associated Transcriptional Regulators. [Abstract]

2025 Feb 6:2025.02.06.636893. PMID: 39975267
Research Square Preprint

2024 Dec 13.
Heliyon

Integrative analysis of the efficacy and pharmacological mechanism of Xuefu Zhuyu decoction in idiopathic pulmonary fibrosis via evidence-based medicine, bioinformatics, and experimental verification. [Abstract]

2024 Sep 20;10(19):e38122. PMID: 39416822
bioRxiv

Senescent fibroblasts in the tumor stroma rewire lung cancer metabolism and plasticity. [Abstract]

2024 Jul 30:2024.07.29.605645. PMID: 39131266
Heliyon

Integrating network analysis and experimental validation to reveal the mechanism of si-jun-zi decoction in the treatment of renal fibrosis. [Abstract]

2024 Aug 2;10(16):e35489. PMID: 39220912
J Tradit Chinese Medical Sci

2024 Jun 12.
Biomed Pharmacother

Senolytics ameliorate the failure of bone regeneration through the cell senescence-related inflammatory signalling pathway. [Abstract]

2024 Jun:175:116606. PMID: 38670048
Pharmacological Research-Modern Chinese Medicine

2024 Mar, 10, 100360.
bioRxiv

2023 Dec 20.
Oxid Med Cell Longev

Quercetin Protects against MPP+/MPTP-Induced Dopaminergic Neuron Death in Parkinson's Disease by Inhibiting Ferroptosis. [Abstract]

2022 Sep 5:2022:7769355. PMID: 36105483
Evid Based Complement Alternat Med

The Core Mechanism of Yiqi Yangjing Decoction Inhibiting Nonsmall-Cell Lung Cancer. [Abstract]

2022 May 9;2022:2256671. PMID: 35586682
Aging (Albany NY)

Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signaling. [Abstract]

2021 Nov 25;13(22):24753-24767. PMID: 34821587
J Mol Liq

23 November 2021, 118164.
Evid Based Complement Alternat Med

Identifying Active Compounds and Mechanism of Camellia nitidissima Chi on Anti-Colon Cancer by Network Pharmacology and Experimental Validation. [Abstract]

2021 Aug 26:2021:7169211. PMID: 34484402
Research Square Preprint

2021. Jul.
International Journal of Human Anatomy

2020 Dec.
Aging

Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin. [Abstract]

2020 Jun 25;12(12):11337-11348. PMID: 32584785
Int J Insect Sci

Do Bioflavonoids in Juniperus virginiana Heartwood Stimulate Oviposition in the Ladybird Coleomegilla maculata?. [Abstract]

2018 Feb 28:10:1179543318758409. PMID: 29531477

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (330.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 16.67 mg/mL (55.15 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3086 mL

16.5431 mL

33.0863 mL

5 mM

0.6617 mL

3.3086 mL

6.6173 mL

10 mM

0.3309 mL

1.6543 mL

3.3086 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 25 mg/mL (82.72 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 50% Propylene glycol 50% Saline

Solubility: 10 mg/mL (33.09 mM); Suspended solution; Need ultrasonic

Protocol 3

Add each solvent one by one: 45% PEG300 5% Tween-80 50% Saline

Solubility: 10 mg/mL (33.09 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Animal Administration^[3]

Mice are inoculated subcutaneously with 5×10⁵ PC-3 cells suspended in 100μL PBS and 2×10⁸ LNCaP cells suspended in 100μL of matrigel and PBS mixture (1:1) on the right back. When xenograft tumors reach a volume of approximately 100 mm³, mice are randomLy assigned to four groups (n=8 each group) and treated intraperitoneally. Therapeutic schedule based on our in vitro results, preliminary experiments and many other researchers' studies is as follows: (1) Vehicle control group: vehicle of quercetin on day 1, vehicle of 2-ME on day 2, (2) Quercetin treated group: quercetin 75 mg/kg on day 1, vehicle of 2-ME on day 2, (3) 2-ME treated group: vehicle of quercetin on day 1, 2-ME 150 mg/kg on day 2, (4) Combination treatment group: quercetin 75 mg/kg on day 1, 2-ME 150 mg/kg on day 2. Two days is a treatment cycle and the whole treatment process lasted for 4 weeks. Tumor sizes are monitored every 2 days using caliper and tumor volume are calculated according to the formula: L×S2×0.5, in which L represents the longest diameter and S represents the shortest diameter of tumor. Mice are weighed as well. At the end of treatment procedure, on day 29, mice are anesthetized with chloral hydrate and sacrificed by cervical dislocation. Xenograft tumors are taken out quickly and weighed. One part of it is put into liquid nitrogen immediately for future biomarker analysis and the other part is fixed in 10% neutral buffered formalin for immunohistochemical analysis. Serum biochemical parameters such as ALT, AST, creatinine and urea nitrogen that reflected drug toxicity are also detected.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Leyre Navarro-Núñez, et al. Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. Fitoterapia. 2010 Mar;81(2):75-80. [Content Brief]

[2]. Yu XB, et al. Inhibitory effects of protein kinase C inhibitors on tumor necrosis factor induced bovine pulmonary artery endothelial cell injuries. Yao Xue Xue Bao. 1996;31(3):176-81. [Content Brief]

[3]. Yang F, et al. Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth. PLoS One. 2015 May 26;10(5):e0128277. [Content Brief]

[4]. Tao Liu, et al. Quercetin alleviates kidney fibrosis by reducing renal tubular epithelial cell senescence through the SIRT1/PINK1/mitophagy axis. Life Sci. 2020 Jul 20;118116. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	3.3086 mL	16.5431 mL	33.0863 mL	82.7157 mL
	5 mM	0.6617 mL	3.3086 mL	6.6173 mL	16.5431 mL
	10 mM	0.3309 mL	1.6543 mL	3.3086 mL	8.2716 mL
	15 mM	0.2206 mL	1.1029 mL	2.2058 mL	5.5144 mL
	20 mM	0.1654 mL	0.8272 mL	1.6543 mL	4.1358 mL
	25 mM	0.1323 mL	0.6617 mL	1.3235 mL	3.3086 mL
	30 mM	0.1103 mL	0.5514 mL	1.1029 mL	2.7572 mL
	40 mM	0.0827 mL	0.4136 mL	0.8272 mL	2.0679 mL
	50 mM	0.0662 mL	0.3309 mL	0.6617 mL	1.6543 mL
DMSO	60 mM	0.0551 mL	0.2757 mL	0.5514 mL	1.3786 mL
	80 mM	0.0414 mL	0.2068 mL	0.4136 mL	1.0339 mL
	100 mM	0.0331 mL	0.1654 mL	0.3309 mL	0.8272 mL

Keywords

Quercetin

224 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Quercetin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Anti-Aging Natural Product Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Dietary Supplement Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library